Systemic treatment in advanced melanoma;Systemische behandlung beim fortgeschrittenen melanom

Onkologe

Volumn 7, Issue 1, 2001, Pages 61-70

  Keilholz, U ^a   Kaufmann, R ^b   Tilgen, W ^c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; ANTINEOPLASTIC AGENT; BCG VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKINE; DACARBAZINE; DOXORUBICIN; FOTEMUSTINE; HISTAMINE; HYDROXYUREA; IFOSFAMIDE; INTERLEUKIN 2; MELPHALAN; MITOMYCIN C; MITOZOLOMIDE; PACLITAXEL; PROCARBAZINE; TAMOXIFEN; TEMOZOLOMIDE; TREOSULFAN; VINBLASTINE; VINDESINE;

BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HUMAN; LYMPH NODE METASTASIS; MELANOMA; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; PALLIATIVE THERAPY; REVIEW;

EID: 0035121427     PISSN: 09478965     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007610170167     Document Type: Review

References (38)

1. Prognostic factors in metastatic melanoma
2. DTIC (NSC-45388) in malignant melanoma: A perspective
3. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III)
4. Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma
5. A randomized phase III study of temozolamide (TMZ) versus dacarbazine (DTIC) in the treatment of patients with advanced metastatic melanoma
6. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: A southwest oncology group study
7. Cis-diamminedichloroplatinum in the treatment of disseminated malignant melanoma
8. Synchronous cisplatin infusion during radiotherapy for the treatment of metastatic melanoma
9. Phase II trial of carboplatin in patients with advanced melanoma
10. WR-2721 and high-dose cisplatin: An active combination in the treatment of metastatic melanoma
11. High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study
12. Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours
13. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases
14. Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC-Melanoma Cooperative Group (MCG)
15. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo
16. Combination chemotherapy in metastatic malignant melanoma: A randomized study of three DTIC-containing combination
17. Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: A Southwest Oncology Group Study
18. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma
19. Cispaltin vinblastin and dacarbazine versus dacarbazine alone in metastatic melanoma
20. Dacarbazine-vindesine versus dacarbazine-vinedesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial
21. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
22. Randomized, double-blind, placebo controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
23. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma
24. A phase III multicener randomized trial of DTIC, cisplatin, BCNU and tamoxifen versus DTIC alone in patients with metastatic melanoma
25. Improved results with the addition of interferonalfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma
26. Interferon-alfa 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: Results of a multi-institutional Australian trial
27. Multicenter randomized trial of dacarbazine alone or in combination of two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma
28. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: An Eastern Cooperative Oncology Group study
29. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon-alfa-2a in patients with advanced melanoma
30. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study
31. Randomized phase II trial of BCDT with or without interferon alpha and interleukin-2 in patients with metastatic melanoma
32. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b
33. IFN α/IL-2 with or without Cisplatinum in metastatic melanoma: A randomized trial of the EORTC Melanoma Cooperative Group
34. Dose-efficacy study of two schedules of high-dose bolus administration of interleukin-2 and alpha-interferon in patients with metastatic melanoma
35. Interferon-α and interleukin-2 in the treatment of malignant melanoma: A comparison of two phase II trials
36. Results of IL-2-based treatment in advanced melanoma: A case-record based analysis of 631 patients
37. Dacarbacine and interferon a with or without interleukin 2 in metastatic melanoma: A randomized phase III multicenter trial of the Dermatologie Cooperative Oncology Group (DeC0G)
38. Chemo- und immuntherapie beim metastasierten malignen melanom